There is a very strong association between sleep disturbance and major depression. The link between the two is so fundamental that some researchers have suggested that a diagnosis of depression in the absence of sleep complaints should be made with caution. Sleep disturbance is one of the key symptoms of the disease, may be the reason that depressed patients first seek help, and is one of the few proven risk factors for suicide. If sleep problems remain after other symptoms are ameliorated, there is a significantly increased risk of relapse and recurrence. Another aspect of the association is the remarkable, if paradoxical, temporary improvement in mood seen after total sleep deprivation in a high proportion of depressed patients.

Incidence of sleep symptoms in depression

Symptoms of disturbed night-time sleep in people with depression have been described extensively in both clinical and epidemiological studies. In clinical samples, difficulty in initiating or maintaining sleep (including early-morning wakening) or both have been reported in about three quarters of all depressed patients. Epidemiological studies have pointed out that insomnia in nondepressed subjects is a risk factor for later development of depression. There is therefore a need for more successful management of sleep disturbance in depression, in order to improve quality of life in these patients and reduce an important factor in depressive relapse and recurrence.

Keywords: sleep; depression; insomnia

Address for correspondence: Professor David Nutt, Psychopharmacology Unit, University of Bristol, Dorothy Hodgkin Building, Whitson Street, Bristol, BS1 3NY, UK (e-mail: david.j.nutt@bris.ac.uk)
the 16-to-24-year age group to 90% in the 55-to-64-year age group. When the authors looked at the value of sleep symptoms as a screening aid for depression, the proportion of participants with depression who reported symptoms of insomnia sufficient to warrant a diagnosis of insomnia (DSM-IV) was 41%, and the proportion without depression and without a diagnosis was 96%. This supports the statement mentioned above that diagnosing depression without sleep complaints needs care.

Hypersomnia is less common, and tends to be a feature of atypical depression, and more prevalent in the young, with about 40% of patients under 30 and 10% of those in their 50s experiencing the symptom, hypersonmia only (iv) 10, and a higher incidence in females of all ages. Some patients experience both insomnia and hypersomnia during the same depressive episode.

### Distress and quality of life

Disturbed sleep is a very distressing symptom which has huge impact on quality of life in depressed patients. We surveyed the views of patients with depression about their symptoms and associated sleep difficulties. In this study, 2800 members of Depression Alliance, a UK-based charity for people with depression, were sent a postal questionnaire. Respondents were asked if, when they are depressed, they suffer from sleep difficulties (Table II). Some 97% reported sleep difficulties during depression and 59% of these indicated that poor sleep significantly affected their quality of life. The majority believed their sleep difficulties started at the same time as their depression. About two thirds had sought extra treatment—such as prescribed sleeping pills, over-the-counter sleeping aids, and extra visits to their doctor—for their sleep problems.

In another recent study, depressed patients reported significantly poorer perceptions of sleep quality and poorer perceptions of life quality and mood than the control group, even though estimates of sleep disturbance were similar. This may indicate that depressed individuals experience more “sleep distress” than healthy individuals.

### Physiological findings in depression

As well as the distressing symptoms of sleep disturbance experienced by patients, changes in objective sleep architecture are well-documented in depression. Compared with normal controls, sleep continuity of depressed sub-
Subjects is often impaired, with increased wakefulness (more frequent and longer periods of wakefulness), and reduced sleep efficiency. Sleep onset latency is significantly increased and total sleep time reduced. Rapid eye movement (REM) latency is often shortened, and the duration of the first REM period is increased (Figure 1). The number of eye movements in REM (REM density) is also increased.

Slow-wave activity (SWA) seen on the electroencephalogram (EEG) during non-REM sleep is a marker of the homeostatic drive to sleep; thus, the amount of SWA is greatest in the first sleep cycle when sleep propensity is high, and gradually diminishes in subsequent cycles as sleep debt is made up and sleep drive diminished. The total amount of SWS is often decreased in depression, compared with normal controls.11 This reduction may be related to decreased regional cerebral blood flow seen in the orbitofrontal and anterior cingulate cortex during slow-wave sleep (SWS) in imaging studies,12 and it may be a consequence of the abnormalities in this area described in depression.13 In addition, reduction in SWS can reflect fragmented sleep in general, such as is seen in depression.

Another anomaly seen in depressed patients is that the normal pattern of SWA decreasing from the first to the last NREM episode is disrupted, with less of a decrease in SWA occurring from the first to the second episode in depressed patients14,15 (Figure 2). This is sometimes expressed as a lower delta sleep ratio (DSR) that is the quotient of SWA in the first to the second non-REM period of sleep.

Some of these sleep architecture abnormalities are present during full clinical remission, and also appear to be associated with an increased risk for relapse.16-18 High REM density and reduced SWS in the first cycle were also present in first-degree relatives of depressed patients in the Munich Vulnerability Study on Affective Disorders, measured on two occasions 4 years apart,19 and in a more recent study, REM density predicted those who had subsequently developed a major depressive episode.20

**Mechanisms of sleep regulation and disturbances in depression**

Research over the past 25 years has revealed that the sleep-wake cycle is regulated by two separate but interacting processes,21 the circadian (C) process and the homeostatic (S), or recovery process.
The C process is that which regulates the daily rhythms of the body and brain. Circadian (24-h) patterns of activity are found in many organs and cells, and the main circadian pacemaker is found in a group of cells in the suprachiasmatic nucleus (SCN) of the hypothalamus. These cells provide an oscillatory pattern of activity which drives rhythms such as sleep-wake activity, hormone release, liver function, etc. This drive from the SCN is innate, self-sustaining, and independent of tiredness or amount of sleep. It is affected markedly by light and to some extent by temperature. Bright light in the morning will delay the clock, and bright light in the morning is necessary to synchronize the clock to a 24-hour rhythm; in constant light or darkness the cycle length is about 24.3 h. All animals have such a clock, and the period and timing appear to be dependent on particular genes, which are similar in fruit flies and mammals.

The drive to sleep from the circadian clock in normal sleepers starts to increase slowly at about 11 PM and gradually reaches a peak at about 4 AM. This provides a sleep-promoting process which continues into mid-morning and then provides a wakefulness-promoting process during the day. The timing of REM sleep is linked to the circadian rhythm, closely mirroring the core temperature. Thus, the maximum propensity for REM sleep is usually after the nadir of core temperature, around 6 AM, and it is less likely to occur during an afternoon and evening nap.21 The homeostatic or recovery drive to sleep (the S process) is wake-dependent, ie, it increases in proportion to the amount of time since last sleep. Its usual maximum is at about 11 PM, or about 16 hours after waking up in the morning, and then decreases during sleep, with a minimum at natural waking in the morning. When sleep has been shorter than usual there is a “sleep debt” which leads to an increase in the S process—this works to ensure that the debt is made up at the next sleep period, by accelerating the time to sleep and possibly by increasing sleep depth and duration.

These two processes interact to promote the onset of sleep when both are high (at the usual bedtime), and maintain sleep when the C process is high and the S process is declining (in the early hours of the morning). SWA (see above) is a marker of the homeostatic drive to sleep; thus, the amount of SWA is greatest in the first sleep cycle when sleep propensity is high, and gradually diminishes in subsequent cycles as sleep debt is made up and sleep drive diminished.
has refined the methods of manipulation of sleep and circadian rhythm to maximize its effects on mood by bringing the sleep period forward, and there have been several strategies proposed to prolong the therapeutic effect such as adding drug interventions and strictly controlling the amount and type of sleep allowed in the following days. It can be argued that this intervention works to increase the pressure for sleep (homeostatic process) and on basic circadian function in the brain, supporting a “phase advance” of circadian rhythm in depression which is corrected by sleep manipulation. Further evidence is gained from studies showing that those patients who respond to sleep deprivation and to light treatment are those in whom phase advance has been demonstrated by actimetry (a technique which measures sleep-wake cycles using movement sensors worn for many weeks on the wrist). There is evidence from animal studies of an immediate increase in 5-HT, noradrenaline, and dopamine function in rat brain after sleep deprivation. Neuroimaging studies provide some evidence that in depressed patients, the metabolic hyperactivity seen in the anterior cingulate in depression is corrected by sleep deprivation. Thus the effects of sleep deprivation may be mediated via multiple brain systems. Sleep in depressed patients may be more sensitive to life events which disrupt daily rhythms. Haynes et al rated these events in a group of depressed patients and measured sleep disruption by actigraphy. Depressed patients who had experienced social rhythm-disrupting events, for instance overseas travel, being fired from a full-time job without immediately starting another, starting full-time college, or marital separation, had much more wakefulness during the night compared with those patients without these events, and this difference was not evident in normal controls.

**Increased risk of depression in insomnia**

The National Institute of Mental Health Epidemiologic Catchment Area study 20 years ago interviewed 7954 adults on two occasions a year apart, and this study first highlighted the strong association between sleep disturbance and subsequent depression. They found that 14% of those who had insomnia at the first interview had developed new major depression a year later. This data has been augmented by several more recent reports of increased risk. Breslau et al, in a survey of 1200 young adults in Michigan, found that the odds ratio of new depression in was 4 times increased in those subjects who had insomnia 3 years earlier, and in a questionnaire survey of adults over 18 in the UK there was a 3-fold increased risk of new depression if subjects had reported one sleep problem occurring “on most nights” a year earlier. Doctors in a prospective study who had complained of insomnia during medical school in the 1950s and 1960s were twice as likely to have developed depression at follow-up in 1990s. It is apparent that sleep problems often appear before other depression symptoms, and that subjective sleep quality worsens before onset of an episode in recurrent depression.

**Residual insomnia: relapse and recurrence**

There is much evidence that effective antidepressant treatments can successfully elicit significant response in depression, but is much less evidence that effective treatment fully addresses the problem of sleep disturbance. Persistent insomnia is one of the most common residual symptoms in patients with incomplete remission. This presents a problem, given the fact that residual insomnia confers greater risk of subsequent depression: in a study of “remit- ted” patients maintained on a selective serotonin reuptake inhibitor (SSRI) and psychotherapy, subjective sleep problems and anxiety were each found to be predictors of early recurrence. The origin of these residual symptoms of insomnia is probably multifactorial, reflecting ongoing functional brain abnormalities as well as adverse effects of some drug treatments, for example SSRI, particularly fluoxetine, can lead to insomnia.

**Implications for treatment**

Anomalies in sleep architecture in depression are linked with treatment outcome; for instance they may predict poor response to cognitive behavioral therapy (CBT) and interpersonal therapy, and more patients experience a recurrence of depression after successful CBT treatment if they have an abnormal sleep profile. Response to antidepressant drug treatment is not predicted by sleep EEG abnormalities; however, placebo nonresponse is more likely in those patients with an abnormal sleep profile. Selective serotonergic drugs are the present first-line therapy for depression, and there is much evidence for the involvement of 5-HT in the pathogenesis of both depres-
sion and sleep disturbance. For instance, rapid tryptophan depletion, which reduces brain 5-HT function, results in a temporary return of depressive symptoms in recovered depressed patients, and a reduction in REM latency. SSRIs which increase 5-HT function increase REM latency, and reduce REM sleep. However, although SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), and venlafaxine are effective and widely used, they may worsen sleep disturbance early in treatment and may leave residual sleep symptoms once mood is improved. Benzodiazepine and Z-drug hypnotics (non-benzodiazepine hypnotics, such as zolpidem and zopiclone) are often required to deal with these adverse effects, which can lead to problems with dependence and withdrawal. However, in a study in which zopiclone was added to fluoxetine in depressed patients there were significant beneficial effects, even in depressive symptoms other than insomnia items. Some antidepressants can have a beneficial effect on sleep. These include mianserin, trazodone, nefazodone, and mirtazapine, as well as the older tricyclic antidepressants. The mechanisms underlying this are complex and relate to interactions (blockade) of certain neurotransmitter receptors—with significant 5-HT antagonist properties being a common theme—though antagonism at histamine H1 and noradrenaline α1 receptors also plays a part for some of these drugs.

In conclusion

Subjective and objective sleep disturbance in depression is prevalent, distressing, and often unresolved by treatment. It indicates significant alterations in brain neurotransmitter function, as well as leading to significant impairments in quality of life and further treatment-seeking by sufferers, so increasing the burden on health care services. There is therefore a need for more successful management of sleep disturbance in depression, in order to improve quality of life in these patients and reduce an important factor in depressive relapse and recurrence.

REFERENCES

1. Jindal RD, Thase ME. Treatment of insomnia associated with clinical depression. Sleep Med Rev. 2004;8:19-30.
2. Agargun MY, Kara H, Solmaz M. Sleep disturbances and suicidal behavior in patients with major depression. J Clin Psychiatry. 1997;58:249-251.
3. Hamilton M. Frequency of symptoms in melancholia (depressive illness). Br J Psychiatry. 1989;154:201-206.
4. Bates WR, Mitchell J, John RA, et al. Clinical features of depression in outpatients with and without co-occurring general medical conditions in STAR*D: confirmatory analysis. Prim Care Companion J Clin Psychiatry. 2007;9:7-15.
5. Breslau N, Roth T, Rosenthal L, Andreischi P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry. 1996;39:411-418.
6. Stewart R, Besset A, Bebbington P, et al. Insomnia comorbidity and impact and hypnotic use by age group in a national survey population aged 16 to 74 years. Sleep. 2006;29:1391-1397.
7. Posternak MA, Zimmerman M. Symptoms of atypical depression. Psychiatry Res. 2001;104:175-181.
8. Katz DA, McHorney CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract. 2002;51:229-235.
9. Paterson LM, Nutt DJ, Wilson SJ NAPSAQ 1: National Patient Sleep Assessment Questionnaire in depression. Int J Psychiatry Clin Pract. 2008;12 Suppl 1.
10. Mayers AG, Van Hooft JC, Baldwin DS. Quantifying subjective assessment of sleep and life-quality in antidepressant-treated depressed patients. Hum Psychopharmacol. 2003;18:21-27.
11. Benca RM, Obermeyer VH, Thisted RA, Gillin JC. Sleep and psychiatric disorders: a meta-analysis. Arch Gen Psychiatry. 1992;49:651-670.
12. Maquet P, Degueldre C, Delfiore G, et al. Functional neuroanatomy of human slow wave sleep. J Neurosci. 1997;17:2807-2812.
13. Drevets WC. Orbitofrontal cortex function and structure in depression. Ann N Y Acad Sci. 2007;1121:499-527.
14. Argyropoulos SV, Wilson SJ. Sleep disturbances in depression and the effects of antidepressants. Int Rev Psychiatry. 2005;17:237-245.
15. Armitage R. Sleep and circadian rhythms in mood disorders. Acta Psychiatr Scand. 2007;116 Suppl:104-115.
16. Gillis D, Jarrett RB, Roifling HP, Rush AJ. Reduced rapid eye movement latency: a predictor of recurrence in depression. Neuropsychopharmacology. 1987;1:33-39.
17. Steiger A, Holsboer F. Nocturnal secretion of prolactin and cortisol and the sleep EEG in patients with major endogenous depression during an acute episode and after full remission. Psychiatry Res. 1997;72:81-88.
18. Rush AJ, Erman MK, Giles DE, et al. Polysomnographic findings in recently drug-free and clinically remitted depressed patients. Arch Gen Psychiatry. 1986;43:878-884.
19. Modell S, Ising M, Holsboer F, Lauer CJ. The Munich Vulnerability Study on Affective Disorders: stability of polysomnographic findings over time. Biol Psychiatry. 2002;52:430-437.
20. Modell S, Lauer CJ. Rapid eye movement (REM) sleep: an endophenotype for depression. Curr Psychiatry Rep. 2007;9:480-485.
21. Borbely AA. A two-process model of sleep regulation. Hum Neurobiol. 1982;1:195-204.
22. Dijk DJ van, Schantz M. Timing and consolidation of human sleep, wakefulness, and performance by a symphony of oscillators. J Biol Rhythms. 2005;20:279-290.
23. Nutt DJ. Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry. 2001;62 Suppl:11-22.
24. Jindal RD, Friedman ES, Berman SR, Fasiczka AL, Howland RH, Thase ME. Effects of sertraline on sleep architecture in patients with depression. J Clin Psychopharmacol. 2003;23:540-548.
25. Benedetti F, Dallaspezia S, Fulgosi MC, et al. Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. Am J Med Genet B Neuropsychiatr Genet. 2007;144:631-635.
26. Serretti A, Cusin C, Benedetti F, et al. Insomnia improvement during antidepressant treatment and CLOCK gene polymorphism. Am J Med Genet B Neuropsychiatr Genet. 2005;137:36-39.
27. Wirz-Justice A, van den Hoofdakker RH. Sleep deprivation in depression: what do we know, where do we go? Biol Psychiatry. 1999;46:445-453.
28. Giedke H. The usefulness of therapeutic sleep deprivation in depression. J Affect Disord. 2004;78:85-86.
Los trastornos del sueño como síntomas nucleares de la depresión

El sueño y la depresión están fuertemente relacionados. Cerca de tres cuartas partes de los pacientes depresivos tienen síntomas de insomnio, y la hiperhemia se presenta en alrededor del 40% de los adultos jóvenes con depresión y en el 10% de los pacientes de mayor edad, con un predominio entre las mujeres. Los síntomas provocan un inmenso distress, tienen un gran impacto en la calidad de vida y constituyen un potente factor de riesgo para el suicidio. Además de la experiencia subjetiva de los síntomas del sueño, en la depresión existen cambios bien documentados en la arquitectura objetiva del sueño. En este artículo se discuten los mecanismos de la regulación del sueño y cómo ellos pueden estar alterados en la depresión. Los síntomas del sueño a menudo no se resuelven con el tratamiento, y aportan un mayor riesgo de recaídas y recurrencias. Los estudios epidemiológicos han señalado que el insomnio en los sujetos sin depresión es un factor de riesgo para que más adelante se desarrolle este cuadro. Por lo tanto, se requiere de un manejo más exitoso de los trastornos del sueño en la depresión para mejorar la calidad de vida de estos pacientes y para reducir un factor importante en las recaídas y recurrencias depresivas.

Les troubles du sommeil, symptôme majeur de dépression

Le sommeil et la dépression sont fortement liés. Environ trois quarts des patients déprimés souffrent d’insomnie et l’hyperhémie existe chez à peu près 40 % des jeunes adultes déprimés et 10 % des patients plus âgés avec une prédominance féminine. Ces symptômes sont responsables d’une grande souffrance, ils diminuent beaucoup la qualité de vie et sont un facteur de risque important de suicide. Les modifications de l’architecture objective du sommeil dans la dépression sont aussi bien documentées que les troubles subjectifs du sommeil. Les mécanismes de régulation du sommeil et la manière dont ils peuvent être perturbés lors de la dépression sont discutés. Les troubles du sommeil persistent souvent en dépit du traitement, et représentent un grand risque de récidive et de rechute. Des études épidémiologiques ont souligné que l’insomnie chez des sujets non déprimés est un facteur de risque de dépression ultérieure. Il est donc nécessaire que les troubles du sommeil soient mieux pris en charge dans la dépression afin d’améliorer la qualité de vie chez ces patients et de réduire ce facteur important de récidive et de rechute dépressive.

29. Hemmeter U, Hatzinger M, Brand S, Holsboer-Trachsler E. Effect of flumazenil-augmentation on microsleep and mood in depressed patients during partial sleep deprivation. J Psychiatr Res. 2007;41:876-884.
30. Benedetti F, Dallasega S, Fulgosi MC, Barbini B, Colombo C, Smeraldi E. Phase advance is an actimetric correlate of antidepressant response to sleep deprivation and light therapy in bipolar depression. Chronobiol Int. 2007;24:921-937.
31. Farooqui SM, Brock JW, Zhou J. Changes in monoamines and their metabolite concentrations in REM sleep-deprived rat forebrain nuclei. Pharmacol Biochem Behav. 1996;54:385-391.
32. Wu JC, Gillin JC, Buchsbaum MS, et al. Sleep deprivation PET correlations of Hamilton symptom improvement ratings with changes in relative glucose metabolism in patients with depression. J Affect Disord. 2008;107:181-186.
33. Smith GS, Reynolds CF, III, Houch PR, et al. Glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depression. J Geriatr Psychiatry. 2002;10:561-567.
34. Haynes PL, McQuaid JR, Ancoli-Israel S, Martin JL. Disrupting life events and the sleep-wake cycle in depression. Psychol Med. 2006;36:1363-1373.
35. Ford DE, Kamerow DB. Epidemiological study of sleep disturbances and psychiatric disorders: an opportunity for prevention? JAMA. 1989;262:1479-1484.
36. Morphy H, Dunn KM, Lewis M, Boardman HF, Croft PR. Epidemiology of insomnia: a longitudinal study in a UK population. Sleep. 2007;30:274-280.
37. Chang PP, Ford DE, Mead LA, Cooper-Patrick L, Klag MJ. Insomnia in young men and subsequent depression. The Johns Hopkins Precursors Study. Am J Epidemiol. 1997;146:105-114.
38. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res. 2003;37:9-15.
39. Perlis ML, Giles DE, Buysse DJ, Tu X, Kupfer DJ. Self-reported sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord. 1997;42:209-212.
40. Carney CE, Segal ZV, Edinger JD, Krystal AD. A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. J Clin Psychiatry. 2007;68:254-260.
41. Dombrovski AY, Mulsant BH, Houch PR, et al. Residual symptoms and recurrence during maintenance treatment of late-life depression. J Affect Disord. 2007;103:77-82.
42. Thase ME, Simons AD, Reynolds CF, III. Abnormal electroencephalographic sleep profiles in major depression: association with response to cognitive-behavior therapy. Arch Gen Psychiatry. 1996;53:99-108.
43. Thase ME, Buysse DJ, Frank E, et al. Which depressed patients will respond to interpersonal psychotherapy? The role of abnormal EEG sleep profiles. Am J Psychiatry. 1997;154:502-509.
44. Heiligenstein JH, Faries DE, Rush AJ, et al. Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients. *Psych Res.* 1994;52:327-339.

45. Delgado PL, Price LH, Miller HL, et al. Serotonin and the neurobiology of depression: effects of tryptophan depletion. *Arch Gen Psychiatry.* 1994;51:865-874.

46. Moore PM, Gillin C, Bhatti T, et al. Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. *Arch Gen Psychiatry.* 1998;55:534-539.

47. Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. *Drugs.* 2005;65:927-947.

48. Hicks JA, Argyropoulos SV, Rich AS, et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. *Br J Psychiatry.* 2002;180:528-535.

49. Diaz-Martinez A, Benassini O, Ontiveros A, et al. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. *Clin Ther.* 1998;20:467-476.

50. Nelson JC, Portera L, Leon AC. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. *J Clin Psychiatry.* 2005;66:1409-1414.

51. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. *Biol Psychiatry.* 2006;59:1052-1060.